These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Allopurinol Medication Adherence as a Mediator of Optimal Outcomes in Gout Management. Coburn BW; Bendlin KA; Sayles H; Meza J; Russell CL; Mikuls TR J Clin Rheumatol; 2017 Sep; 23(6):317-323. PubMed ID: 28816767 [TBL] [Abstract][Full Text] [Related]
4. Adherence to statins and LDL-cholesterol goal attainment. Chi MD; Vansomphone SS; Liu IL; Cheetham C; Green KR; Scott RD; Reynolds K Am J Manag Care; 2014 Apr; 20(4):e105-12. PubMed ID: 24884955 [TBL] [Abstract][Full Text] [Related]
5. Not getting to goal: the clinical costs of noncompliance. Ansell BJ J Manag Care Pharm; 2008 Jul; 14(6 Suppl B):9-15. PubMed ID: 18693783 [TBL] [Abstract][Full Text] [Related]
6. Determinants of glycaemic control in a practice setting: the role of weight loss and treatment adherence (The DELTA Study). McAdam-Marx C; Bellows BK; Unni S; Mukherjee J; Wygant G; Iloeje U; Liberman JN; Ye X; Bloom FJ; Brixner DI Int J Clin Pract; 2014 Nov; 68(11):1309-17. PubMed ID: 25113816 [TBL] [Abstract][Full Text] [Related]
7. Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs. Stacy TA; Egger A J Manag Care Pharm; 2006; 12(9):745-51. PubMed ID: 17249907 [TBL] [Abstract][Full Text] [Related]
9. Understanding Processes, Outcomes, and Contexts in Medication Adherence: The Medication Adherence Context and Outcomes (MACO) Framework. Bartlett Ellis RJ; Haase JE; Ruppar TM Patient Prefer Adherence; 2023; 17():239-248. PubMed ID: 36718437 [TBL] [Abstract][Full Text] [Related]
10. Lost Therapeutic Benefit of Delayed Low-Density Lipoprotein Cholesterol Control in Statin-Treated Patients and Cost-Effectiveness Analysis of Lipid-Lowering Intensification. Marquina C; Morton J; Zomer E; Talic S; Lybrand S; Thomson D; Liew D; Ademi Z Value Health; 2023 Apr; 26(4):498-507. PubMed ID: 36442832 [TBL] [Abstract][Full Text] [Related]
11. [Therapeutic alliance, a stake in schizophrenia]. Charpentier A; Goudemand M; Thomas P Encephale; 2009 Feb; 35(1):80-9. PubMed ID: 19250998 [TBL] [Abstract][Full Text] [Related]
12. Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program. Lawrence DB; Ragucci KR; Long LB; Parris BS; Helfer LA J Manag Care Pharm; 2006; 12(6):466-71. PubMed ID: 16925454 [TBL] [Abstract][Full Text] [Related]
13. [Status of cholesterol goal attainment for the primary and secondary prevention of atherosclerotic cardiovascular disease in dyslipidemia patients receiving lipid-lowering therapy: DYSIS-China subgroup analysis]. Li Y; Zhao SP; Ye P; Yan XW; Mu YM; Wei YD; Hu DY; Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Aug; 44(8):665-70. PubMed ID: 27545124 [TBL] [Abstract][Full Text] [Related]
14. The Effect of Clinical Pharmacist-Led Comprehensive Medication Management on Chronic Disease State Goal Attainment in a Patient-Centered Medical Home. Prudencio J; Cutler T; Roberts S; Marin S; Wilson M J Manag Care Spec Pharm; 2018 May; 24(5):423-429. PubMed ID: 29694290 [TBL] [Abstract][Full Text] [Related]
15. Pharmacist-Led Chronic Disease Management: A Systematic Review of Effectiveness and Harms Compared With Usual Care. Greer N; Bolduc J; Geurkink E; Rector T; Olson K; Koeller E; MacDonald R; Wilt TJ Ann Intern Med; 2016 Jul; 165(1):30-40. PubMed ID: 27111098 [TBL] [Abstract][Full Text] [Related]
16. LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO. Nag SS; Daniel GW; Bullano MF; Kamal-Bahl S; Sajjan SG; Hu H; Alexander C J Manag Care Pharm; 2007 Oct; 13(8):652-63. PubMed ID: 17970603 [TBL] [Abstract][Full Text] [Related]
17. Use of health information technology (HIT) to improve statin adherence and low-density lipoprotein cholesterol goal attainment in high-risk patients: proceedings from a workshop. Cohen JD; Aspry KE; Brown AS; Foody JM; Furman R; Jacobson TA; Karalis DG; Kris-Etherton PM; Laforge R; O'Toole MF; Scott RD; Underberg JA; Valuck TB; Willard KE; Ziajka PE; Ito MK J Clin Lipidol; 2013; 7(6):573-609. PubMed ID: 24314357 [TBL] [Abstract][Full Text] [Related]
18. Lipid-lowering treatment intensity, persistence, adherence and goal attainment in patients with coronary heart disease. Mazhar F; Hjemdahl P; Clase CM; Johnell K; Jernberg T; Carrero JJ Am Heart J; 2022 Sep; 251():78-90. PubMed ID: 35654163 [TBL] [Abstract][Full Text] [Related]
19. Low-density lipoprotein cholesterol goal attainment among high-risk patients: Does a combined intervention targeting patients and providers work? Afonso NM; Nassif G; Aranha AN; Delor B; Cardozo LJ Am J Manag Care; 2006 Oct; 12(10):589-94. PubMed ID: 17026413 [TBL] [Abstract][Full Text] [Related]
20. Lipid management and cholesterol goal attainment in Norway. Ose L; Skjeldestad FE; Bakken IJ; Levorsen A; Alemao EA; Yin DD; Borgström F; Jönsson L Am J Cardiovasc Drugs; 2006; 6(2):121-8. PubMed ID: 16555865 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]